A phase 2 trial of regorafenib as a single agent in patients with chemotherapy‐refractory, advanced, and metastatic biliary tract adenocarcinoma

Author:

Sun Weijing12ORCID,Patel Anuj3,Normolle Daniel4,Patel Krishna5,Ohr James6,Lee James J.6,Bahary Nathan6,Chu Edward6,Streeter Natalie2,Drummond Summer7

Affiliation:

1. University of Kansas School of Medicine Westwood Kansas

2. University of Kansas Cancer Center Westwood Kansas

3. Division of Hematology‐Oncology, Department of Medicine Harvard University and Dana‐Farber Cancer Institute Boston Massachusetts

4. Department of Biostatistics University of Pittsburgh Graduate School of Public Health Pittsburgh Pennsylvania

5. Texas Oncology Round Rock, Texas

6. University of Pittsburgh School of Medicine and Hillman Cancer Center at the University of Pittsburgh Medical Center Pittsburgh Pennsylvania

7. National Institute for Occupational Safety and Health (NIOSH) Research Branch, Centers for Disease Control and Prevention Pittsburgh Pennsylvania

Funder

Bayer HealthCare

National Institutes of Health

Publisher

Wiley

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3